Agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies through Phase 1b
Deal is a major step forward for Fibrocor’s plans to develop FIB918, its monoclonal antibody for Alport Syndrome, a rare disease with very limited treatment options
Fibrocor and MSRD intend to start Phase 1 clinical trials of its monoclonal antibody in 2025
TORONTO, March 5, 2024 /PRNewswire/ — Fibrocor Therapeutics Inc. (‘Fibrocor’ or ‘the Company’), a privately held developer of novel therapeutics to treat fibrosis, today announces that it has entered into a research and development collaboration with the McQuade Center for Strategic Research and Development, LLC (MSRD) to advance its Alport Syndrome program. The agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies through Phase 1b. MSRD, a member of the Otsuka family of pharmaceutical companies, identifies and supports early-stage opportunities that can change the landscape of treatments for mental illness and renal disorders.
FIB918 is now in the IND-enabling phase and Phase 1 clinical trials of the monoclonal antibody are targeted to start in late 2025. Fibrocor and MSRD will be working with patients, advocacy groups and regulators to execute safe, effective and inclusive clinical trials that take patient …